BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 31818702)

  • 1. The evolving role of translocation t(11;14) in the biology, prognosis, and management of multiple myeloma.
    Paner A; Patel P; Dhakal B
    Blood Rev; 2020 May; 41():100643. PubMed ID: 31818702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience.
    Hebraud B; Magrangeas F; Cleynen A; Lauwers-Cances V; Chretien ML; Hulin C; Leleu X; Yon E; Marit G; Karlin L; Roussel M; Stoppa AM; Belhadj K; Voillat L; Garderet L; Macro M; Caillot D; Mohty M; Facon T; Moreau P; Attal M; Munshi N; Corre J; Minvielle S; Avet-Loiseau H
    Blood; 2015 Mar; 125(13):2095-100. PubMed ID: 25636340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytogenetics and Survival of Multiple Myeloma: Isolated and Combined Effects.
    Sergentanis TN; Kastritis E; Terpos E; Dimopoulos MA; Psaltopoulou T
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):335-40. PubMed ID: 27101987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Impact of Cytogenetic Abnormalities in Multiple Myeloma: A Retrospective Analysis of 229 Patients.
    Jian Y; Chen X; Zhou H; Zhu W; Liu N; Geng C; Chen W
    Medicine (Baltimore); 2016 May; 95(19):e3521. PubMed ID: 27175647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.
    Sonneveld P; Avet-Loiseau H; Lonial S; Usmani S; Siegel D; Anderson KC; Chng WJ; Moreau P; Attal M; Kyle RA; Caers J; Hillengass J; San Miguel J; van de Donk NW; Einsele H; Bladé J; Durie BG; Goldschmidt H; Mateos MV; Palumbo A; Orlowski R
    Blood; 2016 Jun; 127(24):2955-62. PubMed ID: 27002115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial.
    Nemec P; Zemanova Z; Kuglik P; Michalova K; Tajtlova J; Kaisarova P; Oltova A; Filkova H; Holzerova M; Balcarkova J; Jarosova M; Rabasova J; Hruba M; Spicka I; Gregora E; Adam Z; Scudla V; Maisnar V; Schutzova M; Hajek R;
    Leuk Lymphoma; 2012 May; 53(5):920-7. PubMed ID: 22023516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Negative prognostic significance of two or more cytogenetic abnormalities in multiple myeloma patients treated with autologous stem cell transplantation.
    Greslikova H; Zaoralova R; Filkova H; Nemec P; Oltova A; Kupska R; Rudolecka P; Smetana J; Pour L; Zahradova L; Krejci M; Buchler T; Adam Z; Hajek R; Kuglik P
    Neoplasma; 2010; 57(2):111-7. PubMed ID: 20099973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The t(11;14)(q13;q32) translocation as a poor prognostic parameter for autologous stem cell transplantation in myeloma patients with extramedullary plasmacytoma.
    Shin HJ; Kim K; Lee JJ; Song MK; Lee EY; Park SH; Kim SH; Jang MA; Kim SJ; Chung JS
    Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):227-35. PubMed ID: 25812994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic significance of cytogenetics and molecular profiling in multiple myeloma.
    Sawyer JR
    Cancer Genet; 2011 Jan; 204(1):3-12. PubMed ID: 21356186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation.
    Neben K; Jauch A; Bertsch U; Heiss C; Hielscher T; Seckinger A; Mors T; Müller NZ; Hillengass J; Raab MS; Ho AD; Hose D; Goldschmidt H
    Haematologica; 2010 Jul; 95(7):1150-7. PubMed ID: 20220069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cytogenetic Abnormalities and Outcomes of 117 Patients with Multiple Myeloma Detected by FISH].
    Zhai B; Zou DD; Yan JJ; Wang N; Wang LL; Zhu HL; Huang WR; Yu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb; 24(1):127-30. PubMed ID: 26913408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Observation on frequency & clinico-pathological significance of various cytogenetic risk groups in multiple myeloma: an experience from India.
    Kadam Amare PS; Jain H; Nikalje S; Sengar M; Menon H; Inamdar N; Subramanian PG; Gujral S; Shet T; Epari S; Nair R
    Indian J Med Res; 2016 Oct; 144(4):536-543. PubMed ID: 28256461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Implications of t(11;14) in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation.
    Takamatsu H; Yamashita T; Kurahashi S; Saitoh T; Kondo T; Maeda T; Nakazawa H; Murata M; Narita T; Kuroda J; Hashimoto H; Kawamura K; Miyamoto T; Honda S; Ichinohe T; Atsuta Y; Sunami K
    Biol Blood Marrow Transplant; 2019 Mar; 25(3):474-479. PubMed ID: 30423479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of t(4;14) translocation in newly diagnosed multiple myeloma patients in novel agent era.
    Geng C; Yang G; Zhou H; Wang H; Li Y; Leng Y; Zhang Z; Jian Y; Chen W
    Hematology; 2023 Dec; 28(1):2161222. PubMed ID: 36607148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Translocation t(11;14) in newly diagnosed patients with multiple myeloma: Is it always favorable?
    Leiba M; Duek A; Amariglio N; Avigdor A; Benyamini N; Hardan I; Zilbershats I; Ganzel C; Shevetz O; Novikov I; Cohen Y; Ishoev G; Rozic G; Nagler A; Trakhtenbrot L
    Genes Chromosomes Cancer; 2016 Sep; 55(9):710-8. PubMed ID: 27152944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic aberrations and immunohistochemical markers as prognostic indicators in multiple myeloma.
    Yeung J; Chang H
    J Clin Pathol; 2008 Jul; 61(7):832-6. PubMed ID: 18077770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics and clinical outcome of high-risk multiple myeloma patients in Korea (KMM 1805).
    Kim K; Kim JS; Yoon SS; Yoon DH; Eom HS; Lee JJ; Yim HW; Park M; Lee H; Min CK;
    Int J Hematol; 2022 Jul; 116(1):110-121. PubMed ID: 35543899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation.
    Kazmi SM; Nusrat M; Gunaydin H; Cornelison AM; Shah N; Kebriaei P; Nieto Y; Parmar S; Popat UR; Oran B; Shah JJ; Orlowski RZ; Champlin RE; Qazilbash MH; Bashir Q
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):687-93. PubMed ID: 26361647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma.
    Binder M; Rajkumar SV; Ketterling RP; Greipp PT; Dispenzieri A; Lacy MQ; Gertz MA; Buadi FK; Hayman SR; Hwa YL; Zeldenrust SR; Lust JA; Russell SJ; Leung N; Kapoor P; Go RS; Gonsalves WI; Kyle RA; Kumar SK
    Blood Cancer J; 2017 Sep; 7(9):e600. PubMed ID: 28862698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Autologous Transplantation in Patients with Multiple Myeloma with t(11;14): A Propensity-Score Matched Analysis.
    Saini N; Ma J; Milton DR; Patel R; Varma A; Bashir Q; Delgado R; Mukherjee A; Rondon G; Popat UR; Hosing CM; Nieto Y; Kebriaei P; Alousi AM; Ahmed S; Tang G; Mehta R; Srour S; Khouri IF; Iyer S; Weber DM; Thomas SK; Lee HC; Manasanch EE; Patel KK; Orlowski RZ; Champlin RE; Qazilbash MH
    Clin Cancer Res; 2019 Nov; 25(22):6781-6787. PubMed ID: 31481508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.